Betahydroxyfentanyl

Summary

β-Hydroxyfentanyl (Fentanol) is an opioid analgesic that is an analogue of fentanyl.

Betahydroxyfentanyl
Clinical data
Other namesβ-hydroxyfentanyl
ATC code
  • none
Legal status
Legal status
Identifiers
  • N-[1-(2-Hydroxy-2-phenylethyl)piperidin-4-yl]-N-phenylpropanamide
CAS Number
  • 78995-10-5
PubChem CID
  • 62278
DrugBank
  • DB01453 checkY
ChemSpider
  • 56079 checkY
UNII
  • 6Q4XAW26T4
KEGG
  • C22749 checkY
Chemical and physical data
FormulaC22H28N2O2
Molar mass352.478 g·mol−1
3D model (JSmol)
  • Interactive image
  • O=C(N(c1ccccc1)C3CCN(CC(O)c2ccccc2)CC3)CC
  • InChI=1S/C22H28N2O2/c1-2-22(26)24(19-11-7-4-8-12-19)20-13-15-23(16-14-20)17-21(25)18-9-5-3-6-10-18/h3-12,20-21,25H,2,13-17H2,1H3 checkY
  • Key:JEFVHLMGRUJLET-UHFFFAOYSA-N checkY
  (verify)

β-Hydroxyfentanyl was sold briefly on the black market in the early 1980s, before the introduction of the Federal Analog Act which for the first time attempted to control entire families of drugs based on their structural similarity rather than scheduling each drug individually as they appeared.[1]

The chemical structure of fentanyl has been used as a basis in modern chemistry for the discovery and nomenclature of many new fentanyl analogues, sometimes called fentalogs.

β-Hydroxyfentanyl has similar effects to fentanyl. Side effects of fentanyl analogs are similar to those of fentanyl itself, which include itching, nausea and potentially serious respiratory depression, which can be life-threatening. Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear.[2]

References edit

  1. ^ Henderson GL (March 1988). "Designer drugs: past history and future prospects". Journal of Forensic Sciences. 33 (2): 569–75. doi:10.1520/JFS11976J. PMID 3286815.
  2. ^ Mounteney J, Giraudon I, Denissov G, Griffiths P (July 2015). "Fentanyls: Are we missing the signs? Highly potent and on the rise in Europe". The International Journal on Drug Policy. 26 (7): 626–31. doi:10.1016/j.drugpo.2015.04.003. PMID 25976511.